Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ( r- O9 m* K+ ~) I0 l: p
& Y( l) B- |. |' a
8 M( h8 n5 m) x# h- n$ ?
Sub-category:
* X7 z! R! L: N+ {Molecular Targets
% o" b# X. n) |7 Q2 K4 G" C3 {. |! S
9 b7 Q, j m) ]$ u% C* d# l+ w3 K% i, j8 E+ p+ w$ z2 _: g
Category:
0 H2 ]6 O* g$ J9 c2 i- v; ZTumor Biology ( {) F% i# `5 G- v/ I$ P' M4 j
! j. B' E7 X' g0 B1 u" [: Q L+ [, S2 d. ]' M0 E: x
Meeting:9 |. m) _# i! I+ q% ^9 P- Y
2011 ASCO Annual Meeting ; B) H/ h( o x
6 [. I! {+ {4 ]7 H; z
* ^8 W! Z: L+ o* K- i' j! P: BSession Type and Session Title:' K$ t; r0 k. T/ P+ i$ c
Poster Discussion Session, Tumor Biology ) |# ]: R- t' j x
; g/ I6 W* _+ i) x0 C* y3 o- r1 z
4 x: A+ s3 V" }, o m4 g: HAbstract No:1 w1 _2 V% N2 \7 K
10517 5 n: P/ Q& O3 T
( k% o( u2 J+ w* Z7 j- r
0 Z* D4 n5 T2 G+ qCitation:
: n8 D) Y b1 P. Y5 B- n8 TJ Clin Oncol 29: 2011 (suppl; abstr 10517) 1 X& ^" v- L5 \$ g; ?
+ u5 r7 {$ y0 c) V
6 {# z' P% o8 j& O. W/ l! qAuthor(s):
" L: ?9 \ C1 ?4 p; {/ ]J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 6 o* ]" _7 }! ?8 e! f
* N, ~8 P5 B( O/ C/ x" x; E7 Q
% Y7 J6 g% V) C; \* O" x C3 s2 F1 Q/ g t( h! ~. f
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
9 g( U5 z8 ?5 k3 V* e" s, Y
# m4 m; c1 Z5 H; z' ^5 B% P& LAbstract Disclosures
( G6 d- c8 [7 }5 d) _# D4 o* a2 }6 y B7 n/ b% H% t: @
Abstract:( b+ [( m, }' P# e7 |4 @
& i) `: Z2 \. H' k( y
( `* {6 k. F! P$ V6 \, q
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation./ m0 O( J4 B9 k# M6 C
1 Z6 d3 X8 c* h# M
4 z2 p U, T: o1 I7 ?% D. G
|
4 m# {6 N- u* g
显身卡
